1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc.

PTIXW
Protagenic Therapeutics, Inc.US flagNASDAQ Capital Market
0.02
USD
+0.00
- -
27,160.00Market Cap
2010 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
40
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-43.58
-791.76
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-20
-1
-1
- -
-2
-2
-3
-2
-3
-5
-4
-5
-6
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-49.29
-1,208.24
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
2
-17
- -
- -
2
1
- -
- -
- -
10
7
4
1
-5
LT Debt
- -
- -
- -
1
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
Total Equity
8
-17
- -
-1
2
1
- -
-1
-1
10
7
4
1
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
22.78
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
4
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
4
3
2
Cash, Cash Equivalents & STI
4
3
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
10
10
7
Payables & Accruals
3
2
2
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-81.86%
-206.65%
-72.38%
Free Cash Flow
45.14%
71.54%
9.42%
Net Income, GAAP
45.59%
30.56%
10.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Garo H. Armen
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
149 Fifth Avenue New York City NY United States of America 10010
IPO Date
Apr 27, 2021
CIK
0001022899
Website
protagenic.com
Similar Companies
Vigil Neuroscience, Inc. (VIGL)
Metacrine, Inc. (MTCR)
Molecular Partners AG (0QXX.L)
Silo Pharma, Inc. (SILO)
KalVista Pharmaceuticals, Inc. (KALV)
ImmunoGen, Inc. (0A8K.L)
Business
Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc. is a New York-based biopharmaceutical company focused on the discovery and development of novel therapeutics targeting stress-related neuropsychiatric and central nervous system (CNS) disorders, including PTSD, depression, anxiety, substance abuse, obesity, and metabolic conditions. Founded in 2004 and headquartered at 149 Fifth Avenue, Suite 500, New York, New York, the company advances a pipeline of approximately six drug candidates, comprising its lead asset PT-00114, a synthetic teneurin C-terminal associated peptide (TCAP) in Phase I/IIa clinical development pursuing a biologics license application pathway with potential regulatory data exclusivity; PHYX-001, a preclinical potassium channel modulator with mechanisms akin to XEN1101 and BHV-7000; multiple cannabinoid-based compounds protected by composition-of-matter intellectual property for CNS, cardiometabolic, and obesity indications including metabolic dysfunction-associated steatotic liver disease; and modified stilbenoid compounds exhibiting preclinical anticonvulsant activity. The company operates primarily in the United States with a global focus on unmet needs in neuropsychiatry and neurodegeneration driven by stress feedback loops. In May 2025, Protagenic Therapeutics completed a transformative all-stock business combination with Phytanix Bio Inc., creating a combined entity with expanded preclinical assets, enhanced CNS expertise from teams experienced in Sativex and Epidiolex at GW Pharmaceuticals, broader patent protection, and diversified pipeline milestones anticipated over the next 18 months; the transaction involved issuing shares, preferred stock, and warrants to Phytanix stockholders, resulting in approximately 35% post-combination ownership for pre-combination Protagenic shareholders on a fully diluted basis, while retaining the Protagenic Therapeutics name and Nasdaq listing under PTIX. In November 2025, the company received a Nasdaq non-compliance notice related to merger financial consolidation delays.